NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM): Assessing Valuation Following Pipeline Expansion, Auvelity Growth, and New Epilepsy Asset
Axsome Therapeutics (AXSM) has been in the spotlight recently as the company expands its pipeline with the exclusive global rights to AZD7325 for epilepsy and continues showing sales momentum for its depression drug Auvelity.
See our latest analysis for Axsome Therapeutics.
Axsome’s series of pipeline wins and strong Auvelity sales have been mirrored in the stock’s momentum, with a 57% year-to-date share price return and a 41% total shareholder return over the past year. Gains have...